SENVELGO DIN 02543427
Status: Marketed
Holder: BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC.
Health Canada record
| Active ingredient(s) | VELAGLIFLOZIN (VELAGLIFLOZIN L-PROLINE MONOHYDRATE) 15 MG |
|---|---|
| Dosage form | Solution |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Veterinary |
| ATC | |
| Original market date | 25-Mar-2024 |
| Current status date | 25-Mar-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Boehringer Ingelheim (Canada) Ltd Ltee — licence 100187, currently licensed, last inspection rating C (2025-03-03).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 32184 | 2023-11-28 | New Drug Submission (NDS) |